once monthly glp 1 Injections of an ultra-long-acting investigational GLP-1 agonist led to significant weight loss in people with overweight or obesity, with reductions continuing after a switch to once-monthly dosing, according to the ongoing VESPER Monthly GLP-1 for Weight Maintenance

GHK peptide inhibits bleomycin-Induced pulmonary fibrosis in mice by suppressing TGF1/Smad-mediated epithelial-to-mesenchymal transition

The drug has demonstrated significant effectiveness in glycemic control while reducing cardiovascular risk factors among patients with type 2 diabetes

The treatment of T2D has shifted from a gluco-centric approach to a broader cardio-renal-metabolic strategy, emphasizing the prevention of cardiovascular and renal events and the improvement of metabolic aspects beyond glucose control such as promoting weight loss

Semaglutide, an unbiased GLP-1 receptor agonist, was included as a positive control, and showed strong taste-aversion effects (Figure 3C)

doi: 10.1194/jlr.R800094-JLR200